{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:36:14Z","timestamp":1790357774299,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s10072-022-06533-7","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T01:55:34Z","timestamp":1669946134000},"page":"1375-1381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["How relevant are cerebral white matter lesions in the D313Y variant of the \u03b1-galactosidase A gene? Neurological, cardiological, laboratory, and MRI data of 21 patients within a follow-up of 3\u00a0years"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1314-1561","authenticated-orcid":false,"given":"Daniel","family":"Strunk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Veltkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G.","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"B\u00f6ttcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Rolfs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Claudius","family":"Schwitalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Kraemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"key":"6533_CR1","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","volume":"372","author":"YA Zarate","year":"2008","unstructured":"Zarate YA, Hopkin RJ (2008) Fabry\u2019s disease. Lancet Lond Engl 372:1427\u20131435. https:\/\/doi.org\/10.1016\/S0140-6736(08)61589-5","journal-title":"Lancet Lond Engl"},{"key":"6533_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","volume":"122","author":"R Schiffmann","year":"2009","unstructured":"Schiffmann R (2009) Fabry disease. Pharmacol Ther 122:65\u201377. https:\/\/doi.org\/10.1016\/j.pharmthera.2009.01.003","journal-title":"Pharmacol Ther"},{"key":"6533_CR3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.cccn.2004.10.019","volume":"353","author":"GE Linthorst","year":"2005","unstructured":"Linthorst GE, Vedder AC, Aerts JMFG, Hollak CEM (2005) Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clin Chim Acta Int J Clin Chem 353:201\u2013203. https:\/\/doi.org\/10.1016\/j.cccn.2004.10.019","journal-title":"Clin Chim Acta Int J Clin Chem"},{"key":"6533_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s10038-017-0366-y","volume":"63","author":"Y-H Lu","year":"2018","unstructured":"Lu Y-H, Huang P-H, Wang L-Y et al (2018) Improvement in the sensitivity of newborn screening for Fabry disease among females through the use of a high-throughput and cost-effective method, DNA mass spectrometry. J Hum Genet 63:1\u20138. https:\/\/doi.org\/10.1038\/s10038-017-0366-y","journal-title":"J Hum Genet"},{"key":"6533_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1136\/postgradmedj-2018-136056","volume":"94","author":"T Cairns","year":"2018","unstructured":"Cairns T, M\u00fcntze J, Gernert J et al (2018) Hot topics in Fabry disease. Postgrad Med J 94:709\u2013713. https:\/\/doi.org\/10.1136\/postgradmedj-2018-136056","journal-title":"Postgrad Med J"},{"key":"6533_CR6","doi-asserted-by":"publisher","first-page":"e71894","DOI":"10.1371\/journal.pone.0071894","volume":"8","author":"T B\u00f6ttcher","year":"2013","unstructured":"B\u00f6ttcher T, Rolfs A, Tanislav C et al (2013) Fabry disease - underestimated in the differential diagnosis of multiple sclerosis? PLoS One 8:e71894. https:\/\/doi.org\/10.1371\/journal.pone.0071894","journal-title":"PLoS One"},{"key":"6533_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","volume":"51","author":"L van der Tol","year":"2014","unstructured":"van der Tol L, Smid BE, Poorthuis BJHM et al (2014) A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet 51:1\u20139. https:\/\/doi.org\/10.1136\/jmedgenet-2013-101857","journal-title":"J Med Genet"},{"key":"6533_CR8","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/jimd.12240","volume":"43","author":"G Effraimidis","year":"2020","unstructured":"Effraimidis G, Rasmussen \u00c5K, Bundgaard H et al (2020) Is the alpha-galactosidase A variant p.Asp313Tyr (p. D313Y) pathogenic for Fabry disease? A systematic review. J Inherit Metab Dis 43:922\u2013933. https:\/\/doi.org\/10.1002\/jimd.12240","journal-title":"J Inherit Metab Dis"},{"key":"6533_CR9","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/cge.13007","volume":"92","author":"M du Moulin","year":"2017","unstructured":"du Moulin M, Koehn AF, Golsari A et al (2017) The mutation p. D313Y is associated with organ manifestation in Fabry disease. Clin Genet 92:528\u2013533. https:\/\/doi.org\/10.1111\/cge.13007","journal-title":"Clin Genet"},{"key":"6533_CR10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1096-7192(03)00136-7","volume":"80","author":"R Froissart","year":"2003","unstructured":"Froissart R, Guffon N, Vanier MT et al (2003) Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab 80:307\u2013314. https:\/\/doi.org\/10.1016\/S1096-7192(03)00136-7","journal-title":"Mol Genet Metab"},{"key":"6533_CR11","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/00365513.2017.1390782","volume":"77","author":"L Hasholt","year":"2017","unstructured":"Hasholt L, Ballegaard M, Bundgaard H et al (2017) The D313Y variant in the GLA gene - no evidence of a pathogenic role in Fabry disease. Scand J Clin Lab Invest 77:617\u2013621. https:\/\/doi.org\/10.1080\/00365513.2017.1390782","journal-title":"Scand J Clin Lab Invest"},{"key":"6533_CR12","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1111\/cge.13237","volume":"93","author":"D Oder","year":"2018","unstructured":"Oder D, Wanner C, Nordbeck P (2018) The D313Y genotype-pathogenic mutation or polymorphism? Clin Genet 93:1257. https:\/\/doi.org\/10.1111\/cge.13237","journal-title":"Clin Genet"},{"key":"6533_CR13","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1177\/1352458516638747","volume":"22","author":"J Becker","year":"2016","unstructured":"Becker J, Rolfs A, Karabul N et al (2016) D313Y mutation in the differential diagnosis of white matter lesions: experiences from a multiple sclerosis outpatient clinic. Mult Scler Houndmills Basingstoke Engl 22:1502\u20131505. https:\/\/doi.org\/10.1177\/1352458516638747","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"6533_CR14","doi-asserted-by":"publisher","first-page":"116757","DOI":"10.1016\/j.jns.2020.116757","volume":"412","author":"C Zompola","year":"2020","unstructured":"Zompola C, Palaiodimou L, Kokotis P et al (2020) The mutation D313Y may be associated with nervous system manifestations in Fabry disease. J Neurol Sci 412:116757. https:\/\/doi.org\/10.1016\/j.jns.2020.116757","journal-title":"J Neurol Sci"},{"key":"6533_CR15","doi-asserted-by":"publisher","first-page":"e55565","DOI":"10.1371\/journal.pone.0055565","volume":"8","author":"M Lenders","year":"2013","unstructured":"Lenders M, Duning T, Schelleckes M et al (2013) Multifocal white matter lesions associated with the D313Y mutation of the \u03b1-galactosidase A gene. PLoS One 8:e55565. https:\/\/doi.org\/10.1371\/journal.pone.0055565","journal-title":"PLoS One"},{"key":"6533_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2214\/ajr.149.2.351","volume":"149","author":"F Fazekas","year":"1987","unstructured":"Fazekas F, Chawluk JB, Alavi A et al (1987) MR signal abnormalities at 1.5 T in Alzheimer\u2019s dementia and normal aging. AJR Am J Roentgenol 149:351\u2013356. https:\/\/doi.org\/10.2214\/ajr.149.2.351","journal-title":"AJR Am J Roentgenol"},{"key":"6533_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S1474-4422(09)70013-4","volume":"8","author":"SM Greenberg","year":"2009","unstructured":"Greenberg SM, Vernooij MW, Cordonnier C et al (2009) Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol 8:165\u2013174. https:\/\/doi.org\/10.1016\/S1474-4422(09)70013-4","journal-title":"Lancet Neurol"},{"key":"6533_CR18","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S1474-4422(13)70124-8","volume":"12","author":"JM Wardlaw","year":"2013","unstructured":"Wardlaw JM, Smith EE, Biessels GJ et al (2013) Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 12:822\u2013838. https:\/\/doi.org\/10.1016\/S1474-4422(13)70124-8","journal-title":"Lancet Neurol"},{"key":"6533_CR19","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1161\/01.str.32.6.1318","volume":"32","author":"LO Wahlund","year":"2001","unstructured":"Wahlund LO, Barkhof F, Fazekas F et al (2001) A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 32:1318\u20131322. https:\/\/doi.org\/10.1161\/01.str.32.6.1318","journal-title":"Stroke"},{"key":"6533_CR20","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/cge.13233","volume":"93","author":"M du Moulin","year":"2018","unstructured":"du Moulin M, Muschol N (2018) p.D313Y is more than just a polymorphism in Fabry disease. Clin Genet 93:1258. https:\/\/doi.org\/10.1111\/cge.13233","journal-title":"Clin Genet"},{"key":"6533_CR21","doi-asserted-by":"publisher","first-page":"e017098","DOI":"10.1136\/bmjopen-2017-017098","volume":"7","author":"K Koulousios","year":"2017","unstructured":"Koulousios K, Stylianou K, Pateinakis P et al (2017) Fabry disease due to D313Y and novel GLA mutations. BMJ Open 7:e017098. https:\/\/doi.org\/10.1136\/bmjopen-2017-017098","journal-title":"BMJ Open"},{"key":"6533_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/8904_2012_154","volume":"7","author":"M Niemann","year":"2013","unstructured":"Niemann M, Rolfs A, Giese A et al (2013) Lyso-Gb3 Indicates that the alpha-galactosidase A mutation D313Y is not clinically relevant for Fabry disease. JIMD Rep 7:99\u2013102. https:\/\/doi.org\/10.1007\/8904_2012_154","journal-title":"JIMD Rep"},{"key":"6533_CR23","doi-asserted-by":"publisher","first-page":"e010422","DOI":"10.1136\/bmjopen-2015-010422","volume":"6","author":"D Oder","year":"2016","unstructured":"Oder D, \u00dc\u00e7eyler N, Liu D et al (2016) Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y. BMJ Open 6:e010422. https:\/\/doi.org\/10.1136\/bmjopen-2015-010422","journal-title":"BMJ Open"},{"key":"6533_CR24","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/mus.27196","volume":"63","author":"K von Cossel","year":"2021","unstructured":"von Cossel K, Muschol N, Friedrich RE et al (2021) Assessment of small fiber neuropathy in patients carrying the non-classical Fabry variant p. D313Y. Muscle Nerve 63:745\u2013750. https:\/\/doi.org\/10.1002\/mus.27196","journal-title":"Muscle Nerve"},{"key":"6533_CR25","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/mus.25082","volume":"53","author":"ACY Chan","year":"2016","unstructured":"Chan ACY, Wilder-Smith EP (2016) Small fiber neuropathy: getting bigger! Muscle Nerve 53:671\u2013682. https:\/\/doi.org\/10.1002\/mus.25082","journal-title":"Muscle Nerve"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06533-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-022-06533-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06533-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T17:05:13Z","timestamp":1679072713000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-022-06533-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["6533"],"URL":"https:\/\/doi.org\/10.1007\/s10072-022-06533-7","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,2]]},"assertion":[{"value":"21 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This work is based on retrospective data collection, obtained from the routine monitoring of patients\u2019 treatments and their clinical evaluation in the hospital setting. As such, and according to national regulations, it does not require specific approval from the ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research ethic and patient consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}